ZachXBT Unmasks $28M Bittensor Hacker via Anime NFT Trail

TheCryptoTimesPublicado em 2025-10-16Última atualização em 2025-10-16

Crypto sleuth ZachXBT has uncovered how $28 million was stolen from Bittensor. In a recent post, he said that he followed a trail that led through anime NFT trades and traced the funds back to a former Bittensor worker after unmasking hidden transactions made through the Railgun crypto mixer.

According to ZachXBT, 32 TAO holders lost funds between May and July 2024 after a malicious PyPi package caused private key leaks. Consequently, the Bittensor network halted operations on July 2, 2024, while developers investigated the breach. He started tracing the stolen TAO tokens that were moved to Ethereum and later exchanged for Monero (XMR) using quick-swap platforms.

Following the crypto trail

ZachXBT followed the stolen funds to a wallet known as 0x09f, which moved about $4.94 million into Railgun in June 2024. He identified three wallets that extracted the funds by comparing the quantity and timing of payments and withdrawals. The trail showed 1,246 ETH, 276,000 USDC, and 19.8 WETH were shifted to Avalanche and then back to Ethereum using the Synapse Bridge.

The investigation took a surprising turn when address 0x1d7 purchased four Killer GF NFTs for 18.64 ETH, grossly overpaying the floor price. Moreover, related wallets 0x0bc7 and 0x5e9c exchanged NFTs between themselves using stolen funds, showing clear wash trading patterns. These unusual trades connected the theft to a wallet tied to “Rusty,” a person using the alias otc_rusty, who once worked as an Opentensor engineer.

Real world links and legal fallout

ZachXBT revealed that Rusty (Ayden B) later admitted ownership of the identified wallets during a civil lawsuit, though he denied involvement in the hack. Another individual, Jon L (0xJones), also became a suspect after deleting messages and deactivating his accounts post-incident.

“It’s extremely rare to see exploits or hacks involve NFT wash trading,” ZachXBT noted, emphasizing how coordinated the addresses appeared. Moreover, he said law enforcement could move forward with criminal proceedings based on these findings.

ZachXBT’s findings show that in crypto, digital trails can still reveal the truth behind hidden transactions. The case reveals that careful tracking and transparency help uncover complex hacks.

Also Read: MIT Brothers on Trial for $25M Crypto Theft Case


Mobile Only Image

Leituras Relacionadas

Haiwei Huaxin's Official Seal Seized by Over a Hundred People, High-Stakes Corporate Battle's 'Nuclear Deterrence' in Action Again

On August 18th, Haowei Huaxin, a semiconductor firm specializing in gallium arsenide and gallium nitride wafers, reported that over a hundred individuals forcibly entered its offices and seized the company's official seals from a safe, including the corporate, contract, and party committee seals. The incident is the latest escalation in a protracted control dispute. Haowei Huaxin, established in 2010, was originally a joint venture. Control became contested after 2021 when Zhenwei Financial Holding injected capital, becoming the largest shareholder (34.01%), while former parent Haite High-Tech's stake was diluted to 33.79%. An agreed-upon governance structure collapsed, leading to mutual accusations. Haite claimed it was locked out of the subsidiary's premises, while also alleging improper management like livestock being kept on the chip fabrication site. After state-owned Qingdao Haiyue Holdings took over Zhenwei's stake in 2023, Haite accused it of illegally seizing control. Despite Haite winning several legal battles in 2024-2026, which affirmed its rights to nominate directors and the chairman, it failed to regain physical control or recover the seals. The stakes are high: market valuations for Haite's stake in Haowei Huaxin are estimated between 3.7 to 5 billion USD, yet it is only valued at about 83 million USD on Haite's books. Losing control effectively jeopardizes a significant portion of Haite's value. In response to the seal seizure, Haite framed it as a "shareholder rights protection" action agreed upon by five shareholders. This mirrors a pattern in Chinese corporate disputes where seizing physical seals becomes a tactic to paralyze the opponent's daily operations, seen in past conflicts at companies like Dangdang and Bitmain. However, such actions don't resolve underlying ownership issues; the opposing party can report the seals stolen, declare them void, and apply for new ones, albeit with significant delay. The incident underscores how fragile corporate governance can devolve into physical confrontations over symbols of authority, with control ultimately determined by law and shareholding, not possession of a seal.

marsbitHá 26m

Haiwei Huaxin's Official Seal Seized by Over a Hundred People, High-Stakes Corporate Battle's 'Nuclear Deterrence' in Action Again

marsbitHá 26m

Bernstein Interprets MRNA's 177% Surge: What's Fundamentals and What's Hype?

Bernstein's analysis of Moderna's 177% stock surge following positive Phase 3 results for its individualized neoantigen therapy (INT) in melanoma distinguishes fundamental drivers from market speculation. The clinical breakthrough is real: the INTerpath-001 trial met its primary and key secondary endpoints, providing crucial validation for mRNA technology in oncology beyond infectious diseases. However, Bernstein argues the magnitude of the stock move cannot be justified by this single trial's fundamentals alone. The surge was amplified by three key factors: 1) A re-rating of Moderna's mRNA platform potential for expansion into other cancers, 2) A massive short squeeze, given ~15% of shares were sold short pre-announcement, and 3) The compelling "cancer vaccine" narrative that fueled broader investor enthusiasm. While the melanoma success is significant, Bernstein cautions that replication in lung, kidney, and bladder cancers—which have different immunogenicity—is not guaranteed. Furthermore, INT's commercial model faces challenges: it's a personalized treatment, not a mass-market vaccine, implying higher production costs and potential margin pressures despite a projected multi-billion dollar peak sales opportunity. The report also notes sector rotation, with some funds moving from crowded AI/semiconductor trades into defensive healthcare stocks, adding further momentum. In conclusion, Bernstein maintains a "Market-Perform" rating and a $45 price target, far below the post-surge price. It views the current valuation as pricing in an optimistic multi-cancer platform success and efficient commercialization that are yet to be proven. The clinical inflection point is clear, but the earnings inflection point awaits validation across future trials and commercial execution.

marsbitHá 26m

Bernstein Interprets MRNA's 177% Surge: What's Fundamentals and What's Hype?

marsbitHá 26m

Trading

Spot
活动图片